Skip to main content

Patterns of Biologic Agent Use in Older Males with Inflammatory Diseases

An Institution-Focused, Observational Post-Marketing Study

Drugs & Aging volume 26, pages 607–615 (2009)Cite this article

Abstract

Background

Little investigation has focused on use of biologic agents in elderly patients with rheumatoid arthritis, spondyloarthropathies, inflammatory bowel disease or psoriasis. Furthermore, studies of drugs for autoimmune diseases that do include elderly populations have tended to include a preponderance of female patients.

Objective

To evaluate the pattern of biologic agent use in older males with inflammatory diseases, including rheumatoid arthritis, the spondyloarthropathies (ankylosing spondylitis, psoriatic arthritis and reactive arthritis), inflammatory bowel disease and psoriasis.

Methods

All prescriptions of biologic agents dispensed by a US Department of Veterans Affairs Medical Center pharmacy in Dallas, Texas, USA, between 1 January 1999 and 31 December 2007 were analysed. Comprehensive chart reviews were undertaken on all non-cancer patients treated with six biologic agents (infliximab, etanercept, adalimumab, abatacept, rituximab and anakinra) to determine the tolerability of the medication and rates of stopping or switching each drug.

Results

A total of 428 patients (mean±SD age 59±12 years) with rheumatoid arthritis (49%), spondyloarthropathy (37%), inflammatory bowel disease (7%) or psoriasis (7%) were treated with biologics at some point over the 9-year study period. The mean number of biologics used was highest in patients with spondyloarthropathies (1.5) [p=0.003], with the mean stop/switch rate for the first biologic agent being lowest in patients with rheumatoid arthritis (47.4%) [p=0.02]. The mean length of time patients remained on their first biologic agent before stopping or switching was greatest in patients with rheumatoid arthritis (21.1 months) [p=0.26]. The biologic with the highest rate of continuation was etanercept for all groups except inflammatory bowel disease.

Conclusion

This experience with biologic agents in older males with inflammatory diseases revealed that the mean number of agents used when rheumatologists managed rheumatoid arthritis and spondyloarthropathies was higher than when gastroenterology or dermatology specialists treated inflammatory bowel disease and psoriasis. The stop/switch rates were lowest among rheumatoid arthritis patients. Rheumatologists treating rheumatoid arthritis tended to keep patients on the first biologic for a longer period of time before stopping/switching. For those patients who remained on their first biologic agent, etanercept was the most commonly continued drug.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Table I
Table II
Table III
Table IV
Table V
Table VI
Table VII

References

  1. Bathon JM, Fleischmann RM, Van der Heijde D, et al. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol 2006 Feb; 33(2): 234–43

    PubMed  CAS  Google Scholar 

  2. Harrison MJ, Kim CA, Silverberg M, et al. Does age bias the aggressive treatment of elderly patients with rheumatoid arthritis? J Rheumatol 2005 Jul; 32(7): 1243–8

    PubMed  CAS  Google Scholar 

  3. Rasch EK, Hirsch R, Paulose-Ram R, et al. Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States: effect of different methods of case classification. Arthritis Rheum 2003 Apr; 48(4): 917–26

    PubMed  Article  Google Scholar 

  4. Kavanaugh AF. Rheumatoid arthritis in the elderly: is it a different disease? Am J Med 1997 Dec 29; 103(6): 40S–8

    PubMed  Article  CAS  Google Scholar 

  5. Fleischmann R, Iqbal I. Risk:benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis. Drugs Aging 2007; 24(3): 239–54

    PubMed  Article  CAS  Google Scholar 

  6. Schiff MH, Yu EB, Weinblatt ME, et al. Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies. Drugs Aging 2006; 23(2): 167–78

    PubMed  Article  CAS  Google Scholar 

  7. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006 Sep; 54(9): 2793–806

    PubMed  Article  CAS  Google Scholar 

  8. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. ATTRACT study group. Lancet 1999 Dec 4; 354(9194): 1932–9

    PubMed  Article  CAS  Google Scholar 

  9. van der Heijde D, Klareskog L, Rodriguez-Valverde V, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006 Apr; 54(4): 1063–74

    PubMed  Article  Google Scholar 

  10. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006 Jan; 54(1): 26–37

    PubMed  Article  CAS  Google Scholar 

  11. Genovese MC, Becker J, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005 Sep 15; 353(11): 1114–23

    PubMed  Article  CAS  Google Scholar 

  12. Cohen SB, Moreland LW, Cush JJ, et al. A multicentre, double blind, randomized, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 2004 Sep 13; 63(9): 1062–8

    PubMed  Article  CAS  Google Scholar 

  13. Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol 2008 Jan 21; 14(3): 354–77

    PubMed  Article  CAS  Google Scholar 

  14. Pardi DS, Loftus EV, Camilleri M. Treatment of inflammatory bowel disease in the elderly: an update. Drugs Aging 2002; 19(5): 355–63

    PubMed  Article  CAS  Google Scholar 

  15. Ljung T, Karlén P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004 Jun; 53(6): 849–53

    PubMed  Article  CAS  Google Scholar 

  16. van Dullemen HM, van Deventer SJ, Hommes DW, et al. Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995 Jul; 109(1): 129–35

    PubMed  Article  Google Scholar 

  17. Gavalas E, Kountouras J, Stergiopoulos C, et al. Efficacy and safety of infliximab in steroid-dependent ulcerative colitis patients. Hepatogastroenterology 2007 Jun; 54(76): 1074–9

    PubMed  CAS  Google Scholar 

  18. Braun J, Baraliakos X, Brandt J, et al. Therapy of ankylosing spondylitis. Part II: biological therapies in the spondyloarthritides. Scand J Rheumatol 2005 May; 34(3): 178–90

    PubMed  Article  CAS  Google Scholar 

  19. Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005 Aug 27; 64(8): 1150–7

    PubMed  Article  CAS  Google Scholar 

  20. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum 2005 Apr; 52(4): 1227–36

    PubMed  Article  CAS  Google Scholar 

  21. Weinberg JM, Saini R, Tutrone WD. Biologic therapy for psoriasis — the first wave: infliximab, etanercept, efalizumab, and alefacept. J Drugs Dermatol 2002 Dec; 1(3): 303–10

    PubMed  Google Scholar 

  22. Antoni C, Manger B. Infliximab for psoriasis and psoriatic arthritis. Clin Exp Rheumatol 2002 Nov; 20(6): S122–5

    PubMed  CAS  Google Scholar 

  23. Ornetti P, Chevillotte H, Zerrak A, et al. Anti-tumour necrosis factor-alpha therapy for rheumatoid and other inflammatory arthropathies: update on safety in older patients. Drugs Aging 2006; 23(11): 855–60

    PubMed  Article  CAS  Google Scholar 

  24. Fleischmann RM, Baumgartner SW, Tindall EA, et al. Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results. J Rheumatol 2003 Apr; 30(4): 691–6

    PubMed  CAS  Google Scholar 

  25. Fleischmann R, Baumgartner SW, Weisman MH, et al. Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis 2006 Mar 8; 65(3): 379–84

    PubMed  Article  CAS  Google Scholar 

  26. Chevillotte-Maillard H, Ornetti P, Mistrih R, et al. Survival and safety of treatment with infliximab in the elderly population. Rheumatology (Oxford) 2005 May 10; 44(5): 695–6

    Article  CAS  Google Scholar 

  27. Maillard H, Ornetti P, Grimault L, et al. Severe pyogenic infections in patients taking infliximab: a regional cohort study. Joint Bone Spine 2005 Jul 28; 72(4): 330–4

    PubMed  Article  Google Scholar 

  28. Papadopoulos IA, Katsimbri P, Alamanos Y, et al. Early rheumatoid arthritis patients: relationship of age. Rheumatol Int 2003 Mar 15; 23(2): 70–4

    PubMed  Google Scholar 

  29. Fact sheet: facts about the Department of Veterans Affairs. Veterans Affairs [online]. Available from URL: http://www.va.gov/ofcadmin/docs/vaorgbb.pdf [Accessed 2009 Jul 17]

  30. Hyrich KL, Lunt M, Watson KD, et al. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007 Jan; 56(1): 13–20

    PubMed  Article  CAS  Google Scholar 

  31. Hyrich KL, Lunt M, Dixon WG, et al. Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. Rheumatology (Oxford) 2008 Jul 17; 47(7): 1000–5

    Article  CAS  Google Scholar 

  32. Brocq O, Plubel Y, Breuil V, et al. Etanercept-infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti TNFalpha. Presse Med 2002 Nov 23; 31(39): 1836–9

    PubMed  CAS  Google Scholar 

  33. Gomez-Reino JJ, Carmona L. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006 Jan 6; 8(1):R29

    PubMed  Article  Google Scholar 

  34. Conti F, Ceccarelli F, Marocchi E, et al. Switching tumour necrosis factor α antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann Rheum Dis 2007 Jul; 66(7): 1393–7

    PubMed  Article  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this study. The authors have no conflicts of interest that are directly relevant to the content of this study.

Author information

Affiliations

  1. University of Texas Southwestern Medical Center, Dallas, Texas, USA

    Suong Tran, Roderick S. Hooker PhD, PA & Andreas Reimold

  2. Department of Veterans Affairs, 4500 S. Lancaster Road, Dallas, Texas, 75216-7191, USA

    Suong Tran, Roderick S. Hooker PhD, PA & Andreas Reimold

  3. Dallas VA Research Corporation, Dallas, Texas, USA

    Daisha J. Cipher

Authors
  1. Suong Tran
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roderick S. Hooker PhD, PA
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daisha J. Cipher
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andreas Reimold
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roderick S. Hooker PhD, PA.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Tran, S., Hooker, R.S., Cipher, D.J. et al. Patterns of Biologic Agent Use in Older Males with Inflammatory Diseases. Drugs Aging 26, 607–615 (2009). https://doi.org/10.2165/11316350-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11316350-000000000-00000

Keywords

  • Rheumatoid Arthritis
  • Inflammatory Bowel Disease
  • Psoriasis
  • Infliximab
  • Etanercept